| Time of up-dosing |
Up to peak GPS |
After peak GPS |
Total |
| Total number of patients, N |
198 |
52 |
250 |
| Median age range), years |
26.5 (6-73) |
29.5 (5-50) |
27.0 (5-73) |
| Gender, N (%) |
|
|
|
| males |
101 (51.0%) |
23 (44.2%) |
124 (49.6%) |
| females |
97 (49.0%) |
29 (55.8%) |
126 (50.4%) |
| Duration since diagnosis of grass pollen allergy, mean ± SD, years |
3.2 ± 5.4 |
5.5 ± 9.7 |
3.7 ± 6.6 |
| Patients with moderate to severe symptoms, N (%) |
|
|
|
| Nasal symptoms |
183 (92.4%) |
49 (94.3%) |
232 (92.8%) |
| Eye symptoms |
163 (82.3%) |
42 (80.8%) |
205 (82.0%) |
| Patients withknown concomitant allergies, N (%) |
116 (60.1%) |
38 (74.5%) |
154 (63.1%) |
| tree pollen |
82 (41.4%) |
23 (44.2%) |
105 (42.0%) |
| house dust mites |
43 (21.7%) |
17 (32.7%) |
60 (24.0%) |
| animal epithelia |
38 (19.2%) |
11 (21.2%) |
49 (19.6%) |
| Patients with asthma, N (%) |
43 (21.7%) |
10 (19.2%) |
53 (21.2%) |
| Patients first treated with SIT, N (%) |
176 (88.9%) |
43 (82.7%) |
219 (87.6%) |
| Patients who used symptomatic drugs in previous GPS |
168 (84.8%) |
44 (84.6%) |
212 (84.8%) |
|
